<DOC>
	<DOCNO>NCT00208520</DOCNO>
	<brief_summary>Most patient prescribed valproate first antiepileptic drug . It unknown best second-line drug patient become seizure free valproate . This lead Dutch Epilepsy Clinics Foundation ( SEIN ) start SLICE study . Adult patient partial and/or tonic-clonic seizure , insufficiently respond valproate , recruit study . These patient randomize receive one three drug . Patients wil initially use drug next valproate . Neurologists 20 general hospital en neurologist SEIN participate study .</brief_summary>
	<brief_title>Second-Line Treatment Choice Epilepsy</brief_title>
	<detailed_description>The purpose project compare several antiepileptic drug give adult patient epilepsy become seizure free valproate first-line antiepileptic drug . The drug first evaluate combination valproate case success ( seizure reduction 50 % ) also evaluate monotherapy . Patients become seizure free valproate identify neurologist participate hospital . When patient willing participate , randomize one three drug : carbamazepine , lamotrigine levetiracetam . In phase 1 project keep use valproate . The randomized second-line drug titrate first dose level effectiveness combination evaluate . When seizure persist adverse effect allow , add-on drug titrate second dose level effectiveness combination evaluate . When seizure still continue adverse effect allow , add-on drug titrate third final dose level . When patient become seizure free combination final level adverse effect prevent dose increase high level , combination fail phase 1 . When patient become seizure free combination , combination deem success patient . A patient proceed phase 2 , least experienced ï‚±50 % seizure reduction . In phase 2 project second-line drug give monotherapy . This mean valproate withdrawn . The dose second drug increase accordingly . The effectiveness drug monotherapy evaluate . The combined result phase 1 2 enable u interpret result . When patient become seizure free combination phase 1 , stay seizure free phase 2 , efficacy combination attribute add-on drug . When patient develop seizure , efficacy combination attribute combination . The primary outcome measure percentage seizure free . Secondary outcome measure adverse effect result clinimetric epilepsy scale . Serum level measure project . The projected sample size group lower 75 patient per group 20 patient per group . At moment , neurologists 20 general hospital collaborate project . Inclusion patient continue June 2006 . The follow-up patient analysis result carry projected end project .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Adult patient generalize tonicclonic , complex partial and/or simple partial seizure . The seizure welldefined accord International Classification Epileptic Seizures ( 1 ) . Therefore , accurate history adequate neurophysiological data present case order confirm diagnosis . Patients valproate monotherapy seizure free maximal dose tolerate . Patients able understand patient information concern study able give inform consent . Patients fail VPA monotherapy cause lack seizure control maximally tolerate dose ( unable tolerate low maintenance dose VPA , idiosyncratic reaction , noncompliance ) Absence seizure juvenile myoclonic epilepsy Acute progressive neurological disorder Alcohol substance abuse History severe psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Valproate</keyword>
	<keyword>Levetiracetam</keyword>
	<keyword>Lamotrigine</keyword>
	<keyword>Carbamazepine</keyword>
</DOC>